Since IDO-1 is also a target of interest in neuro-immuno-oncology, in principle, lessons learned from the oncology experience and IDO-1 drugs developed for cancer indications could be leveraged as an advanced starting point in the evaluation of the therapeutic utility of IDO-1 inhibition for CNS disease indications, such as AD and elderly onset depression. The gene discussed is IDO1; the disease is Alzheimer disease.